| Age of onset | Peak between 15–35 years, though onset can range from childhood to the 7th decade |
| Sex ratio | Male-to-female ratio approximately 3:1 to 5:1. The sex bias suggests a protective role of estrogen or X-linked modifier genes |
| Penetrance | Only ~50% of male carriers and ~10% of female carriers develop clinical disease, indicating strong modifying factors beyond the primary mtDNA mutation (Yu-Wai-Man et al., 2009 [@yuwaiman2009]) |
| mtDNA haplogroup background | European haplogroup J is associated with increased penetrance of the m.11778G>A and m.14484T>C mutations (Hudson et al., 2007 [@puomila2007]) |
| X-linked modifiers | A putative modifier locus on the X chromosome has been proposed to explain the male predominance, though specific genes remain unidentified |
| YARS2 and PRICKLE3 | Candidate nuclear modifier genes identified through linkage studies in specific LHON pedigrees |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No comments yet. Be the first to comment!
No comments yet. Be the first to comment!